Cellectar Biosciences, Inc. — FY 2022 Form 10-K
Reporting period: Year ended December 31, 2022. This is an annual filing, not a standalone fourth-quarter report. Cellectar is a clinical-stage oncology company developing phospholipid drug conjugates (PDCs); it reported no product revenue in the financial statements.
Key financial metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $19.22 million | $17.59 million |
| General and administrative expense | $9.59 million | $6.54 million |
| Operating loss | $28.81 million | $24.13 million |
| Net loss | $28.60 million | $24.12 million |
| Net loss per share | $4.05 | $4.35 |
| Cash used in operating activities | $25.22 million | $22.57 million |
| Cash and cash equivalents at year-end | $19.87 million | $35.70 million |
Margins are not meaningful because the company reported no revenue. The filing reports no conventional borrowings; year-end liabilities were $6.08 million, including $0.60 million of lease liabilities. Current assets were $20.53 million and current liabilities were $5.53 million. Accumulated deficit was $179.50 million. Approximately $19.4 million of cash was uninsured at year-end.
Material changes and financing
- Net loss increased by about $4.48 million year over year. R&D expense rose 9%, mainly due to manufacturing and preclinical costs; G&A rose 47%, primarily from professional fees, travel and personnel costs.
- Cash declined $15.84 million during 2022. The company raised approximately $9.61 million net in an October registered offering and concurrent private placements of common stock, pre-funded warrants and warrants.
- The October financing included warrants for up to 5.15 million common shares at $1.96 per share, plus 1.88 million pre-funded warrants exercisable at $0.00001. These securities create potential dilution.
- A 1-for-10 reverse stock split took effect in July 2022. Common shares outstanding were 9.39 million at year-end.
Business, outlook and risks
- Lead candidate iopofosine (CLR 131) is being studied in several cancer indications. The CLOVER-WaM pivotal Phase 2 study in relapsed/refractory Waldenstrom’s macroglobulinemia was enrolling; following its 2022 interim safety and futility assessment, the independent monitoring committee recommended continued enrollment without a dose change. The filing does not provide a clear pivotal efficacy result.
- Other programs include Phase 2 studies in multiple myeloma and CNS lymphoma, pediatric development, and preclinical PDC programs. The company also reported a $1.9 million NCI grant for pediatric high-grade glioma research.
- The company said year-end cash would fund basic budgeted operations into the fourth quarter of 2023. It expects continued operating losses and needs additional financing to execute its plans. Management stated that funding is not assured; the auditor’s report and financial statements identify substantial doubt about the company’s ability to continue as a going concern within one year of issuance.
- Key risks include dependence on external capital; clinical-trial uncertainty and recruitment delays, including COVID-related site resourcing issues; reliance on AtomVie as the primary iopofosine drug-product supplier; regulatory and manufacturing hurdles; and competition, reimbursement and potential Nasdaq listing issues.
- Reported iopofosine adverse events included fatigue and blood-cell decreases such as thrombocytopenia, anemia and neutropenia. The filing also notes fatalities due to infection among treated patients; safety and benefit remain subject to ongoing clinical evaluation.
- A lawsuit concerning intellectual property was resolved in November 2022. Claims were dismissed, and Cellectar obtained an irrevocable, non-exclusive license to the patents at issue.
Most important facts for investors to verify
- Cash runway assumptions, actual subsequent cash use, and the availability, terms and dilution impact of future financing.
- Current CLOVER-WaM enrollment, the precise interim assessment findings, primary-endpoint results and regulatory path.
- Updated efficacy and safety data for iopofosine across trials, including serious adverse events and infection-related fatalities.
- Continuity, capacity and regulatory readiness of the company’s primary supplier and other clinical manufacturing arrangements.
- Potential dilution from outstanding warrants, pre-funded warrants, stock options and any future equity issuance.